Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02021682 · ClinicalTrials.gov registry record
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
A clinical trial, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 58
- Enrollment target
NCT02021682 is a clinical trial that has completed, run by Washington University School of Medicine. The registered enrollment target is 58 participants.
The verdict
NCT02021682 has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how amyloid-beta (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding of these processes may lead to improved understanding of AD, earlier diagnosis and a way to evaluate treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02021682
The ClinicalTrials.gov registry entry for NCT02021682 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02021682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02021682 about?
NCT02021682 is a clinical study titled "CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease". Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how amyloid-beta (a protein thought to cause AD) is made, transported and cleared in the human body. Better unders...
What is the current status of trial NCT02021682?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2013-12. Estimated completion is 2017-07.
Who is sponsoring clinical trial NCT02021682?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.